1. Signaling Pathways
  2. GPCR/G Protein
    Immunology/Inflammation
  3. CXCR
  4. CXCR7 Isoform

CXCR7

 

CXCR7 Related Products (10):

Cat. No. Product Name Effect Purity
  • HY-10046
    Plerixafor
    Antagonist ≥98.0%
    Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC50 of 44 nM.
  • HY-50912
    Plerixafor octahydrochloride
    Antagonist ≥98.0%
    Plerixafor octahydrochloride (AMD3100 octahydrochloride) is a selective CXCR4 antagonist with an IC50 of 44 nM.
  • HY-139643
    CXCR7 antagonist-1
    Antagonist 99.97%
    CXCR7 antagonist-1 is a CXCR7 antagonist that inhibits the binding of the SDF-1 chemokine (also known as the CXCL12 chemokine) or I-TAC (also known as CXCL11) to the chemokine receptor CXCR7.
  • HY-P1102
    TC14012
    Modulator 99.43%
    TC14012, a serum-stable derivative of T140, is a selective and peptidomimetic CXCR4 antagonist with an IC50 of 19.3 nM.
  • HY-110318
    VUF11207 fumarate
    Agonist 98.92%
    VUF11207 fumarate is a CXCR7 agonist that binds specifically to CXCR7.
  • HY-139643A
    CXCR7 antagonist-1 hydrochloride
    Antagonist
    CXCR7 antagonist-1 hydrochloride is a CXCR7 antagonist that inhibits the binding of the SDF-1 chemokine (also known as the CXCL12 chemokine) or I-TAC (also known as CXCL11) to the chemokine receptor CXCR7.
  • HY-W019787
    BAM-12P
    Activator
    BAM-12P, an endogenous opioid peptide, is a novel pro-Met-enkephalin.
  • HY-112154
    CXCR7 modulator 2
    Modulator 98.39%
    CXCR7 modulator 2 is a modulator of C-X-C Chemokine Receptor Type 7 (CXCR7), with a Ki of 13 nM.
  • HY-107987
    CXCR7 modulator 1
    Modulator 99.67%
    CXCR7 modulator 1 (compound 25) is a potent and orally bioavailable peptoid hybrid CXCR7 modulator, with a Ki of 9 nM.
  • HY-P1102A
    TC14012 TFA
    Modulator
    TC14012 TFA, a serum-stable derivative of T140, is a selective and peptidomimetic CXCR4 antagonist with an IC50 of 19.3 nM.